{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:13:46Z","timestamp":1788585226314,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2019-01059"],"award-info":[{"award-number":["2019-01059"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Heart and Lung Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Secondary hyperparathyroidism (sHPT) develops frequently in patients with chronic kidney disease (CKD). However, the burden and long-term impact of sHPT on the risk of adverse health outcomes are not well studied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We evaluated all adults receiving nephrologist care in Stockholm during 2006\u201311 who were not undergoing kidney replacement therapy and had not developed sHPT. Incident sHPT was identified by using clinical diagnoses, initiated medications or two consecutive parathyroid hormone (PTH) measurements \u2265130\u2009pg\/mL. We characterized sHPT incidence by estimated glomerular filtration rate (eGFR) strata, evaluated clinical predictors and quantified the association between incident sHPT (time-varying exposure) and the risk of fractures, CKD progression, major adverse cardiovascular events (MACEs) and death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 2556 adults with CKD Stages 1\u20135 (mean age 66\u2009years, 38% women), of whom 784 developed sHPT during follow-up. The incidence of sHPT increased with advancing CKD: from 57 cases\/1000 person-years in CKD Stage G3 to 230 cases\/1000 person-years in Stage G5. In multivariable analyses, low eGFR was the strongest sHPT predictor, followed by young age, male sex and diabetes. Incident sHPT was associated with a 1.3-fold (95% confidence interval 1.1\u20131.8) increased risk of death, a 2.2-fold (1.42\u20133.28) higher risk of MACEs, a 5.0-fold (3.5\u20137.2) higher risk of CKD progression and a 1.3-fold (1.5\u20132.2) higher risk of fractures. Results were consistent in stratified analyses and after excluding early events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our findings illustrate the burden of sHPT in advanced CKD and highlight the susceptibility for adverse outcomes of patients developing sHPT. This may inform clinical decisions regarding pre-sHPT risk stratification, PTH monitoring and risk-prevention strategies post-sHPT development.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfab006","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T23:14:58Z","timestamp":1610579698000},"page":"2213-2220","source":"Crossref","is-referenced-by-count":60,"title":["Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease"],"prefix":"10.1093","volume":"14","author":[{"given":"Yang","family":"Xu","sequence":"first","affiliation":[{"name":"Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8650-5795","authenticated-orcid":false,"given":"Marie","family":"Evans","sequence":"additional","affiliation":[{"name":"Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Soro","sequence":"additional","affiliation":[{"name":"Global HEOR, GPMA, Vifor Pharma, Opfikon, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barany","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, CLINTEC, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan Jesus","family":"Carrero","sequence":"additional","affiliation":[{"name":"Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"2021093019461841800_sfab006-B1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021093019461841800_sfab006-B2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1681\/ASN.V1161141","article-title":"Cell biology of parathyroid gland hyperplasia in chronic renal failure","volume":"11","author":"Dr\u00fceke","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2021093019461841800_sfab006-B3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.endonu.2015.05.006","article-title":"Prevalencia del hiperparatiroidismo secundario en pacientes con enfermedad renal cr\u00f3nica estadios 3 y 4 atendidos en medicina interna","volume":"62","author":"Bureo","year":"2015","journal-title":"Endocrinol Nutr"},{"key":"2021093019461841800_sfab006-B4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4158\/EP.14.1.18","article-title":"Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"14","author":"Andress","year":"2008","journal-title":"Endocr Pract"},{"key":"2021093019461841800_sfab006-B6","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1185\/03007990802437943","article-title":"Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients","volume":"24","author":"Schumock","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2021093019461841800_sfab006-B7","doi-asserted-by":"crossref","first-page":"c54","DOI":"10.1159\/000228076","article-title":"Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients","volume":"113","author":"Schumock","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"2021093019461841800_sfab006-B8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3892\/etm.2016.3438","article-title":"Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease","volume":"12","author":"Wei","year":"2016","journal-title":"Exp Ther Med"},{"key":"2021093019461841800_sfab006-B9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11255-010-9897-2","article-title":"Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease","volume":"44","author":"Lishmanov","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"2021093019461841800_sfab006-B10","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/ki.2008.64","article-title":"Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bone.2014.01.016","article-title":"Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients","volume":"61","author":"Streja","year":"2014","journal-title":"Bone"},{"key":"2021093019461841800_sfab006-B12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2021093019461841800_sfab006-B14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.2012.465","article-title":"Pathologic cervical fracture in a patient with secondary hyperparathyroidism","volume":"83","author":"Faur","year":"2013","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2021093019461841800_sfab006-B16","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00198-019-05033-3","article-title":"Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease","volume":"30","author":"Geng","year":"2019","journal-title":"Osteoporos Int"},{"key":"2021093019461841800_sfab006-B17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ckj\/sfv117","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness","volume":"9","author":"Runesson","year":"2016","journal-title":"Clin Kidney J"},{"key":"2021093019461841800_sfab006-B18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021093019461841800_sfab006-B19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.ajkd.2018.08.013","article-title":"Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium","volume":"73","author":"Inker","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2021093019461841800_sfab006-B22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.2779","article-title":"Parathyroid hormone and the use of diuretics and calcium-channel blockers: the multi-ethnic study of atherosclerosis","volume":"31","author":"Zaheer","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2021093019461841800_sfab006-B23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/dc11-2235","article-title":"Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease","volume":"35","author":"Wahl","year":"2012","journal-title":"Diabetes Care"},{"key":"2021093019461841800_sfab006-B24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1210\/jc.2010-0980","article-title":"Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?","volume":"96","author":"Thrailkill","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2021093019461841800_sfab006-B25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2021093019461841800_sfab006-B26","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1097\/01.ASN.0000141961.49723.BC","article-title":"Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism","volume":"15","author":"Cuppari","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2021093019461841800_sfab006-B27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/ndt\/gfq541","article-title":"Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients","volume":"26","author":"Drechsler","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2021093019461841800_sfab006-B28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","article-title":"PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer","volume":"23","author":"Kir","year":"2016","journal-title":"Cell Metab"},{"key":"2021093019461841800_sfab006-B29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"Tentori","year":"2014","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2021093019461841800_sfab006-B31","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1093\/ndt\/gft290","article-title":"Impact of age on survival predictability of bone turnover markers in hemodialysis patients","volume":"28","author":"Lertdumrongluk","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2021093019461841800_sfab006-B32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1523-1755.1999.00617.x","article-title":"Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure","volume":"56","author":"Rix","year":"1999","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B33","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1681\/ASN.2007010022","article-title":"Fracture risk after parathyroidectomy among chronic hemodialysis patients","volume":"18","author":"Rudser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2021093019461841800_sfab006-B34","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2021093019461841800_sfab006-B35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int"},{"key":"2021093019461841800_sfab006-B36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bone.2014.12.008","article-title":"Diabetes and fracture risk in older U.S. adults","volume":"82","author":"Looker","year":"2016","journal-title":"Bone"},{"key":"2021093019461841800_sfab006-B37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11154-016-9397-5","article-title":"Osteoporosis in patients with diabetes after kidney transplantation","volume":"18","author":"Gosmanova","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"2021093019461841800_sfab006-B38","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"2021093019461841800_sfab006-B39","first-page":"CD006023","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"8","author":"Ruospo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2021093019461841800_sfab006-B40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.03940510","article-title":"Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"6","author":"Kandula","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021093019461841800_sfab006-B41","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/ndt\/gfw354","article-title":"Prevalence and recognition of chronic kidney disease in Stockholm healthcare","volume":"31","author":"Gasparini","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2021093019461841800_sfab006-B42","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/archinte.168.20.2268","article-title":"Patient awareness of chronic kidney disease: trends and predictors","volume":"168","author":"Plantinga","year":"2008","journal-title":"Arch Intern Med"},{"key":"2021093019461841800_sfab006-B43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00774-009-0048-8","article-title":"Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes","volume":"27","author":"Smith","year":"2009","journal-title":"J Bone Miner Metab"},{"key":"2021093019461841800_sfab006-B44","doi-asserted-by":"crossref","first-page":"248","DOI":"10.18553\/jmcp.2003.9.3.248","article-title":"Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population","volume":"9","author":"London","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"2021093019461841800_sfab006-B45","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1046\/j.1523-1755.2003.00930.x","article-title":"The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease","volume":"63","author":"Winkelmayer","year":"2003","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfab006\/36780910\/sfab006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/10\/2213\/40489011\/sfab006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/10\/2213\/40489011\/sfab006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T23:42:11Z","timestamp":1633045331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/10\/2213\/6104553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,1,20]]},"published-print":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfab006","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,1,20]]}}}